Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

Eli Lilly found itself in a pharmaceutical pickle after its CFO claimed telehealth partners don’t compound key weight-loss ...

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has cemented its position as a leading ...

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

U.S. equities gained at midday on better-than-expected consumer inflation news and a trade agreement between the U.S. and ...

Whether you want a medicated solution or an all-natural fix, these pro-backed recommendations can start helping in as little ...

Officials at the FDA say they want to speed up approvals for new drugs and devices using tech like the new "Elsa" AI system. More news is on other uses of AI in health care, Eli Lilly refusing to work ...

Hims & Hers leverages ZAVA's expertise to enter Europe's weight-loss market, boosting growth and profitability. Read what ...

Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant investor attention recently. Perhaps you, like many others, have been caught up ...

NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / PointFive, a leading innovator of cloud management and pioneer of Cloud ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...